Increased In vivo efficacy of lenalidomide by addition of piroctone olamine

In Vivo

Volumn 25, Issue 1, 2011, Pages 99-103

  Kim, Young ^a   Alpmann, Petra ^a   Blaum Feder, Sabine ^a   Krämer, Simon ^a   Endo, Tomoyuki ^b,c   Lu, Desheng ^b   Carson, Dennis ^b   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta catenin; Lenalidomide; Lymphoma; Myeloma; Piroctone olamine; Wnt

Indexed keywords

BETA CATENIN; LENALIDOMIDE; PIROCTONE ETHANOLAMINE; THALIDOMIDE; WNT PROTEIN;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; TUMOR CELL LINE;

EID: 79952012729     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE and Gertz MA: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13): 4050-4053, 2005. (Pubitemid 41775908)
2. Cadigan KM and Liu YI: Wnt signaling: complexity at the surface. J Cell Sci 119: 395-402, 2006.
3. 2+ pathways. Oncogene 18: 7860-7872, 1999. (Pubitemid 30066232)
4. You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, Evan G, Kitajewski J and Wang CY: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440, 2002. (Pubitemid 34839807)
5. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
6. Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004. (Pubitemid 39150127)
7. Nusse R: Wnt signaling in disease and in development. Cell Res 15: 28-32, 2005.
8. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
9. Willert K and Jones KA: Wnt signaling: Is the party in the nucleus? Genes Dev 20: 1394-1404, 2006.
10. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M and Carson DA: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci 101: 3118-3123, 2004. (Pubitemid 38327744)
11. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug-resistant and -sensitive cell lines. Cancer Res 48: 3622-3625, 1988.
12. Hoffman BD, Hanauske-Abel HM, Flint A and Lalande M: A new class of reversible cell cycle inhibitors. Cytometry 12: 26-32, 1991.
13. Fukuda Y, Nakashima S and Ujiie T: The in vitro effect of a collagenolytic enzyme inhibitor on lesion development in root dentin. Am J Dent 22(2): 115-121, 2009.
14. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IGH, Kipps TJ and Carson DA: Ethacrynic acid exhibitis selective cytotoxicity to chronic Lymphocytic leikemia cells by inhibition of the Wnt/beta-catenin pathway. PloS one 4(12): e8294, 2009.
15. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B and Shaughnessy JD Jr.: The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109: 4470-4477, 2007. (Pubitemid 46743417)
16. Knobloch J and Rüther U: Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7: 1121-1127, 2008. (Pubitemid 351749260)